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Natural killer T cells (NKT cells) are selected in the thymus by self-glycolipid 
antigens presented by CD1d molecules. It is currently thought that one specifi  c 
component of the lysosomal processing pathway, which leads to the produc-
tion of isoglobotrihexosylceramide (iGb3), is essential for normal NKT cell 
development. New evidence now shows that NKT cell development can be 
disrupted by a diverse range of mutations that interfere with different elements 
of the lysosomal processing and degradation of glycolipids. This suggests that 
lysosomal storage diseases (LSDs) in general, rather than one specifi  c defect, 
can disrupt CD1d antigen presentation, leading to impaired development of 
NKT cells.
Chewing the fat on natural killer T cell development
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NKT cells are a specialized lineage of 
T cells that recognize glycolipid anti-
gens presented by the major histocom-
patibility complex class I–like molecule 
CD1d (1). Current evidence suggests 
that NKT cells branch away from 
the mainstream T cell lineage at the 
CD4+CD8+ double positive (DP) stage 
of development in the thymus (2). 
NKT cells are derived from the small 
fraction of thymocytes that have ran-
domly generated CD1d-reactive T cell 
receptors (typically comprising Vα14-
Jα18 combined with either Vβ8.2, 
Vβ7, or Vβ2). When these cells en-
counter CD1d molecules expressed by 
other DP thymocytes (the cell type re-
sponsible for intrathymic NKT cell se-
lection), they diff  erentiate toward the 
NKT cell lineage. The newly selected 
NKT cells are clearly distinct from 
other T cell types. They adopt an acti-
vated/memory phenotype, express NK 
receptors, and gain the capacity to pro-
duce high levels of cytokines within 
minutes of T cell receptor ligation (1).
Considering that the frequency of 
NKT cells in humans is highly variable 
between individuals and that low NKT 
cell numbers are associated with a var-
iety of immunological defects in mice 
and humans (3), it is critical that we 
  understand the factors that regulate 
their development.
Gadola et al. (on p. 2293 in this is-
sue [4]) show that mutations in several 
lysosomal proteins cause impaired NKT 
cell development. This study suggests 
that normal lipid traffi   cking  and  pro-
cessing in the lysosome is critical for 
CD1d loading and NKT cell develop-
ment and invites a reexamination of 
earlier fi  ndings suggesting that there is 
only one major selecting ligand for 
NKT cells (5).
The hunt for selecting ligands
One of the major questions in the NKT 
cell fi   eld is the identity of the glycol-
ipid  ligands responsible for the positive 
  sel  ection of NKT cells. CD1d mole-
cules most likely bind their ligands as 
they   recirculate through the endosomal/
lysosomal pathway of the DP cells before 
returning to the cell membrane to pre-
sent the ligands to developing NKT cells 
(6–8). The prototypic NKT cell antigen is 
α-galacytosylceramide (α-GalCer) (9, 10), 
which is recognized by most, if not all, 
NKT cells in mice and humans. α-
  GalCer, a glycosphin  golipid derived from 
marine sponges, is a potent agonist ligand 
that can init  iate NKT cell–  dependent im-
mune responses, leading to enhanced im-
munity to tumors and infectious organisms 
and suppression of certain autoimmune 
diseases (3). Several other nonmammali-
an agonist glycolipid ligands for NKT 
cells have recently been identifi  ed (9, 11). 
Although these ligands provide impor-
tant insight into targets for NKT cell–
  dependent immune responses, they 
cannot serve as endogenous ligands for 
NKT cell selection.
Two years ago, a report from Zhou 
et al. (5) provided a breakthrough in the 
fi  eld, off  ering strong evidence that iGb3, 
a mammalian glycosphingolipid, is a 
CD1d-dependent agonist for NKT cells 
from mice and humans. This report also 
demonstrated that Hexb mutant mice, a 
model for human Sandhoff   disease, had 
markedly impaired NKT cell develop-
ment (5). The Hexb gene product is a 
key subunit of the enzymes (β-hexosa-
minidase A and B; see text box)  necessary 
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A word about 𝗃-hexosaminidase nomenclature. 
Lysosomal β-hexosaminidase enzymes are dimers. β-Hexosaminidase A is 
a heterodimer consisting of α and β subunits, β-hexosaminidase B is a β 
subunit homodimer, and β-hexosaminidase S is an α subunit homodimer. 
Thus, a mutation in the α subunit (Hexa−/−; Tay-Sachs disease) affects 
β-hexosaminidase A and S but not β-hexosaminidase B, whereas a mutation 
in the β subunit (Hexb−/−; Sandhoff disease) affects both β-hexosaminidase 
A and B enzymes. Both β-hexosaminidase A and B enzymes degrade iGb4 to 
iGb3 in lysosomes, meaning that this particular pathway is disrupted in Sand-
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for the lysosomal degradation of iGb4 
to iGb3 (5), as well as for the production 
of other glycolipid products. Among 
these products, however, only iGb3 is 
an NKT cell agonist. Assuming NKT 
cells are selected by self-agonists, this 
  result implicated iGb3 as the prime 
  candidate NKT cell–selecting ligand 
(Fig. 1, A and B) (5, 12).
The case for iGb3 as a mammalian 
NKT cell agonist ligand is strong and 
has been verifi  ed by several other studies 
(13–16), including a report that demon-
strated a role for this ligand in the activa-
tion of NKT cells in the   periphery (15). 
However, whether this ligand is unique 
in its ability to mediate intrathymic 
NKT cell selection has yet to be defi  ni-
tively demonstrated. It is also unclear 
whether these results can be translated 
to humans, as the synthesis of iGb3 in 
humans has not been formally demon-
strated. A recent paper stated (as 
unpublished data) that iGb3 synthase 
mRNA was not detectable in a range 
of human tissues, including thymus (17). 
In contrast, however, Zhou et al. (5) 
demonstrated, using an inhibitory lectin, 
that NKT cells respond to human den-
dritic cells via an NKT cell antigen 
comprising a Galα1-3Gal linkage. 
Given that the only two enzymes that 
can produce this linkage are α-galactos-
yltransferase and iGb3 synthase and that 
humans lack the former (17), this result 
strongly suggested the presence of iGb3 
in human cells.
The importance of good digestion
Gadola et al. provide intriguing new 
results that suggest an alternative ex-
planation for the NKT cell defi  ciency 
observed in Hexb mutant Sandhoff   mice 
(4). Sandhoff   disease is one of several 
diseases of lysosomal glycolipid process-
ing, broadly classed as LSDs, in which 
impaired traffi   cking or degradation re-
sults in an accumulation of lysosomal 
glycolipids and impaired cellular func-
tion (18). In their study, (4) Gadola et al. 
examined several mouse models of LSD, 
each carrying a mutation that aff  ects a 
diff  erent aspect of lysosomal glycolipid 
processing. These included mice with 
defi  ciencies in the lysosomal enzymes 
β-hexaminidase A and B (Hexb−/−, 
a model of Sandhoff    disease),  β-hex-
aminidase A and S (Hexa−/−, a model 
of Tay-Sachs disease and late-onset Tay-
Sachs disease), β-galactosidase (a model 
of GM1 gangliosidosis), and α-galacto-
sidase (a model of Fabry disease). The 
group also studied a mouse model of 
Niemann-Pick disease type C1 in which 
the mutation causes impaired choles-
terol and glycolipid traffi   cking from the 
late endosome, a very diff  erent cause of 
LSD. Whereas the Hexb mutants (Sand-
hoff  ) have impaired hydrolysis of iGb4 
to iGb3, this step should be intact in 
mice lacking functional Hexa (Tay-Sachs), 
β-galactosidase (GM1 gangliosidosis), 
or  α-galactosidase (Fabry). Indeed, α-
galactosidase mutant cells accumulate 
globotriaosyl ceramides, such as iGb3, as 
the breakdown of these glycolipids to 
lactosylceramide is inhibited (18).
Despite the diversity of these mu-
tations, the pathways aff  ected, and the 
  glycolipids that are stored, NKT cell 
development was impaired in each 
model, albeit to varying extents. In ad-
dition,   antigen-presenting cells from 
Hexb−/− (Sandhoff  ),  β-galactosidase–
defi   cient (GM1 gangliosidosis), and 
Niemann-Pick disease type C1 mice had 
impaired ability to process and present 
an exogenous disaccharide analogue 
of α-GalCer, Galα1-2GalCer galacto-
sylceramide (which can be processed 
and presented as an NKT cell antigen 
by normal cells), even though this pro-
cessing event is independent of Hexb 
and β-galactosidase. Collectively, these 
observations prompted the authors to 
challenge the notion that the failure to 
degrade iGb4 to iGb3 in Hexb−/− mice 
is specifi  cally responsible for impaired 
NKT cell development. They instead 
suggest that any disruption of lysosomal 
glycolipid processing that results in 
LSD will potentially aff  ect CD1d load-
ing and, consequently, impair NKT cell 
development (Fig. 1 C).
Figure 1.  CD1d is initially expressed on the cell surface loaded with phospholipids but then 
traffi  cs to lysosomes where phospholipids are exchanged with glycolipids. (A) In normal cells, 
lysosomal glycolipid degradation, which is controlled by various hydrolytic enzymes and lipid transfer 
proteins, results in a series of glycolipids, such as iG3b, becoming available for CD1d loading (red ar-
rows). The current model holds that degradation of iGb4 by the enzymes β-hexosaminidase A and B 
generates iGb3 in the lysosome; iGb3 is thought to be the main glycolipid involved in NKT cell selec-
tion. (B) A mutated Hexb gene (Sandhoff disease) causes a defi  ciency in the β-hexosaminidase A and B 
enzymes (see text box), thus removing iGb3 from the pool of lysosomal glycolipids available for CD1d 
loading. (C) The new model put forward by Gadola et al. proposes that any disruption of lysosomal 
processing (including but not limited to Sandhoff disease) nonspecifi  cally alters the repertoire of gly-
colipids available for CD1d loading to the point that NKT cell development is inhibited (reference 4).COMMENTARY
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How LSDs might derail NKT 
cell development
Lysosomal degradation of glycolipids 
  involves at least two steps. First, glyco-
lipids (and some proteins) in the limiting 
membrane (the outer lysosomal mem-
brane) of the lysosome are packaged into 
intraluminal vesicles that bud into the 
luminal space of the lysosome. Second, 
these intraluminal vesicles are degraded 
by the sequential action of glycosidases 
and lipases, often in concert with saposin 
proteins that help to solubilize mem-
brane-embedded apolar glycolipid spe-
cies (18). It is conceivable that CD1d 
proteins located in the limiting mem-
brane of the lysosome could sample gly-
colipids from both the limiting membrane 
and/or from the intra  luminal vesicles 
(Fig. 1). Defects in glycolipid degrada-
tion could thus lead to global defects 
in both the generation and composition 
of the intraluminal vesicles, as well as 
in their breakdown. The perturbation of 
these processes might aff  ect the pro-
duction and/or presentation of specifi  c 
glycolipid species (such as iGb3) and, 
therefore, the reduced loading of CD1d 
with ligands needed for NKT cell selec-
tion. Alternatively, the increase in gly-
colipids in the lumen of the lysosome 
may simply dilute out ligands such as 
iGb3, decreasing the probability that 
CD1d will be loaded with NKT cell–
  selecting ligands.
Putting things in perspective
The Gadola study highlights the po-
tential importance of proper lysosome 
function and glycolipid processing for 
appropriate CD1d loading. Although 
it does not eliminate iGb3 as a candi-
date selecting ligand, it appears to 
weaken the evidence that iGb3 is the 
exclusive selecting ligand, a hypothesis 
originally based on the use of Hexb 
mutant mice (5). It must be pointed 
out that some results in the study by 
Gadola et al. are in apparent confl  ict 
with other reports (5, 19). In particu-
lar, the original paper describing iGb3 
as an NKT cell ligand (5) included 
  experiments to test whether the de-
velopment of LSD in Hexb   mutants 
  nonspecifi   cally disrupted glycolipid 
processing. In contrast to the   fi  ndings 
reported in the Gadola study (4), Zhou 
et al. (5) showed that Hexb−/− antigen-
presenting cells processed and presented 
  disaccharide Galα1-2GalCer galac-
tosylceramide normally, providing 
convincing evidence that this LSD 
did not cause a general disruption of 
glycolipid processing. Furthermore, 
whereas Gadola et al. showed that 
α-galactosidase (Fabry) mutant mice 
had impaired NKT cell development 
(consistent with an earlier report that 
claimed reduced NKT cell numbers 
in the spleen [6]), no such defect was 
observed in a 2004 paper from Zhou 
et al. (19).
Reasons for these discrepancies are 
unclear but may relate to diff  erent dis-
ease states caused by mouse age, sex, or 
other variables. The Fabry disease mice 
are particularly interesting in the con-
text of iGb3, because this disease should 
lead to an accumulation of this ligand 
in the lysosome. If iGb3 is a major se-
lecting ligand for NKT cells, it might 
be predicted that NKT cell develop-
ment would be enhanced in these 
mice. However, it is also possible that 
an excess of agonist ligand could cause 
negative selection of NKT cells (20), 
which would represent a distinct cause 
of impaired NKT cell development. 
Lastly, the Hexa−/− (Tay-Sachs) mice 
only showed impaired NKT cell num-
bers in the liver, which appeared to 
correlate with a more mild LSD that 
aff  ected the liver but spared the thymus 
and spleen. Although this seems rea-
sonable, it is inconsistent with reports 
that peripheral homeostasis of NKT cells 
is largely independent of peripheral 
CD1d-mediated signals (21, 22).
Clearly, there is considerable con-
troversy surrounding the use of these 
LSD mouse models, and it will be im-
portant to independently assess these 
variables, as they have a major bearing 
on the interpretation of studies of NKT 
cell development and function using 
such models.
Outstanding questions and 
the way forward
iGb3 is currently the only mammalian 
glycolipid with clear agonist activity for 
a majority of NKT cells and remains 
the strongest candidate ligand for NKT 
cell selection. It is important to add that 
even if LSD by itself impairs NKT cell 
development, this does not automati-
cally exclude iGb3 as the candidate li-
gand (Fig. 1). However, more defi  nitive 
studies are clearly necessary to test the 
hypothesis that iGb3 is required for 
normal NKT cell development in mice 
and humans. The production of iGb3 
synthase–defi   cient mice is the most 
  obvious approach, as this defect would 
aff  ect iGb3 biosynthesis in the early se-
cretory pathway rather than its degrada-
tion in the lysosome, and the mice would 
thus be unlikely to develop LSD.
Regardless of whether iGb3 is the 
key selecting ligand in mice, it re-
mains unclear whether humans express 
a functional iGb3 synthase gene and, 
more specifi  cally, whether iGb3 is pro-
duced in human thymus. Given that 
human NKT cells are highly variable 
in frequency but are typically 10–100 
times less frequent than mouse NKT 
cells (23), the identifi  cation and mea-
surement of the human NKT cell se-
lecting ligands are challenging but 
important objectives.
An analysis of the NKT cell com-
partment of humans with various LSDs 
will also be very valuable. The prediction 
from the Gadola study would be that 
these individuals would have lower NKT 
cell numbers compared with healthy in-
dividuals. A recent report demonstrated 
that patients with Gaucher disease (an 
LSD caused by glucocerebrosidase defi  -
ciency) undergoing enzyme replacement 
therapy had a modest increase in the per-
centage of Vα24+ cells within the CD4 
T cell pool compared with healthy con-
trols (24), which appears to support this 
hypothesis. However, some caveats to 
this study are that Gaucher disease itself 
was not associated with reduced Vα24 
cells compared with healthy controls 
and, furthermore, that Vα24 alone is a 
not a reliable marker of NKT cells. Fur-
ther studies of patients with Gaucher 
  disease and other LSDs are clearly 
necessary.
Finally, it will now be interesting 
to study NKT cell development and gly-
colipid presentation by CD1d in mice 
or  cell lines that have other defects in 2232  LYSOSOMAL STORAGE DISEASE AND NKT CELL DEVELOPMENT | Godfrey et al.
  lysosomal function to further test the 
  extent to which LSDs generally disrupt 
NKT cell development. For example, 
analysis of mice with defects in the for-
mation of the intraluminal vesicles (25) 
will provide a distinct model of LSD, 
and it may also provide some insights as 
to whether glycolipids are loaded onto 
CD1 proteins from the limiting mem-
brane of the lysosome or from the intra-
luminal vesicles.
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